Starving cancer

December 19, 2011 By Fabio Bergamin
Starving cancer
Microscopic photograph of a tumour section surrounded by healthy tissue. Tumour blood vessels are represented in red, healthy tissue is colored in green. Credit: Philochem AG

A research group led by ETH Zurich professor Dario Neri have developed a new strategy to fight cancer. Blood vessels in the environment of tumors are killed with a new molecule which leads to the "starvation” of the tumor. Compared to currently applied treatments, this new strategy has a series of advantages.

Modern therapeutics produced by biotechnological methods, often are based on antibodies. „Commonly these antibodies are used unmodified, which is – with a few exceptions – not very efficient though”, says Dario Neri, Professor of Biomacromolecules at the Institute of Pharmaceutical Sciences of ETH Zurich. For this reason, an important trend in the development of new chemotherapeutics is to "arm” the antibodies, for example by coupling them to a cytotoxic drug, in order to increase their efficacy.

The ETH researchers under the supervision of Prof. Neri developed such an antibody in collaboration with Philochem, a spin-off company of ETH Zurich. They experimentally showed that cancer bearing mice survived twice as long as without treatment. The researchers published their work in the journal Angewandte Chemie International Edition.

Lesser risk of resistances

Prof. Neri’s promising strategy differs from other armed antibodies currently in development with respect to several points. The macromolecules of the ETH researchers are not directed towards the themselves but towards newly formed within the surroundings of the . This blocks the delivery of nutrients to the tumor and inhibits its growth. This strategy has the advantage that not only single specific tumor species can be fought but theoretically all cancer species. In addition, the researchers expect that the cancer cells develop resistances against chemotherapeutics more slowly.

Another distinctive feature of the new macromolecules is that they do not recognize proteins on the surface of cancer cells as commonly being the rule, but the tissue around the cells, the so called extracellular matrix. The advantage of this is that the cytotoxic drug is liberated already in the surrounding of the tumor and therefore also reaches sites of the tumor, which are not accessible with conventional macromolecules.

Further investigations necessary

Thirdly, in the strategy of Prof. Neri the antibody and the pharmaceutical drug are not coupled via a linker-molecule but via a direct chemical bond. "This simplifies the synthesis of the macromolecules and makes them more controllable", says the first-author of the study, ETH researcher Gonçalo Bernardes. Further, a series of problems are avoided which are potentially caused by these linker-molecules.

"We could show with the new study that the strategy works”, says Prof. Neri. Applied in mice, the new macromolecule showed a measurable anticancer effect. However, mice were not healed from cancer. "For this reason, further investigations are necessary before the new molecule can be tested on humans in clinical trials.”

Explore further: New target identified to stop the spread of breast cancer

More information: Bernardes GJL, et al: A Traceless Vascular Targeting Antibody-drug Conjugate for Cancer Therapy, Angewandte Chemie International Edition (2011) doi: 10.1002/anie.201106527

Related Stories

New target identified to stop the spread of breast cancer

November 10, 2011
A new potential target to slow breast cancer tumor progression and metastasis has been identified by a team of researchers led by Dr. Richard Kremer from the Research Institute of the McGill University Health Centre (RI-MUHC). ...

Group develops method of killing cancer cells with antibodies and light

November 7, 2011
(Medical Xpress) -- Traditionally, there are three major ways to combat cancer in people: surgical removal, radiation therapy and chemotherapy. And while all three have been proven to be effective in treating some types of ...

Recommended for you

Study uncovers potential 'silver bullet' for preventing and treating colon cancer

July 26, 2017
In preclinical experiments, researchers at VCU Massey Cancer Center have uncovered a new way in which colon cancer develops, as well as a potential "silver bullet" for preventing and treating it. The findings may extend to ...

Compound shows promise in treating melanoma

July 26, 2017
While past attempts to treat melanoma failed to meet expectations, an international team of researchers are hopeful that a compound they tested on both mice and on human cells in a petri dish takes a positive step toward ...

Understanding cell segregation mechanisms that help prevent cancer spread

July 26, 2017
Scientists have uncovered how cells are kept in the right place as the body develops, which may shed light on what causes invasive cancer cells to migrate.

Study may explain failure of retinoic acid trials against breast cancer

July 25, 2017
Estrogen-positive breast cancers are often treated with anti-estrogen therapies. But about half of these cancers contain a subpopulation of cells marked by the protein cytokeratin 5 (CK5), which resists treatment—and breast ...

Breaking the genetic resistance of lung cancer and melanoma

July 25, 2017
Researchers from Monash University and the Memorial Sloan Kettering Cancer Center (MSKCC, New York) have discovered why some cancers – particularly lung cancer and melanoma – are able to quickly develop deadly resistance ...

Physical activity could combat fatigue, cognitive decline in cancer survivors

July 25, 2017
A new study indicates that cancer patients and survivors have a ready weapon against fatigue and "chemo brain": a brisk walk.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.